{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:18:46Z","timestamp":1778221126590,"version":"3.51.4"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Epstein-Barr virus (EBV) is a ubiquitous human \u03b3-herpesvirus associated with a wide spectrum of diseases, ranging from autoimmune diseases to malignancies. Recognized as the first human oncogenic virus, multifaceted pathogenesis of EBV-associated diseases has been extensively explored. However, recent evidence suggests that EBV modulates immune cell function to influence the initiation and progression of associated diseases. Expressing a diverse repertoire of viral RNAs and proteins, EBV not only maintains latency with multiple immune evasion mechanisms, but also modulates host cell biology and sculpts a disease-specific immune microenvironment through dynamic interactions with various immune cells like T cells, B cells, macrophages, natural killer cells, and dendritic cells. Correspondingly, an increasing number of immunotherapies targeted T cells, B cells and virus itself have been developed for improved efficacy, including monoclonal antibodies, chimeric antigen receptor T cell (CAR-T) therapy, vaccines, and lytic induction strategies. In this review, regulatory roles of EBV in modulating the immune microenvironment in different context of disease and emerging therapeutic strategies targeted the underlying molecular mechanisms have been systematically discussed. Future research should aim to elucidate the precise molecular pathways involved, identify key therapeutic targets, characterize intra- and inter-tumor heterogeneity, and develop virus-directed strategies to fundamentally counteract EBV-induced immunopathogenic effects.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1794394","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:52:07Z","timestamp":1778219527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Epstein-Barr virus associated diseases: Immune alterations and targeted approaches"],"prefix":"10.3389","volume":"17","author":[{"given":"Shijia","family":"Cao","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00543-7","article-title":"Epstein-Barr virus\u2014recent advances","volume":"3","author":"Macsween","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus (EBV): biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01928-2","article-title":"Nasopharyngeal carcinoma: current views on the tumor microenvironment\u2019s impact on drug resistance and clinical outcomes","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104357","article-title":"Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma","volume":"86","author":"Chow","year":"2022","journal-title":"eBioMedicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821752116","article-title":"EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells","volume":"116","author":"Leong","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.935205","article-title":"EBV infection and its regulated metabolic reprogramming in nasopharyngeal tumorigenesis","volume":"12","author":"Yang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk4898","article-title":"A metabolic dependency of EBV can be targeted to hinder B cell transformation","volume":"385","author":"M\u00fcller-Durovic","year":"2024","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03440-20","article-title":"Multiple viral microRNAs regulate interferon release and signaling early during infection with Epstein-Barr virus","volume":"12","author":"Bouvet","year":"2021","journal-title":"mBio"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011186","article-title":"Suppression of cGAS- and RIG-I-mediated innate immune signaling by Epstein-Barr virus deubiquitinase BPLF1","volume":"19","author":"Lui","year":"2023","journal-title":"PloS Pathog"},{"key":"B11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.it.2025.03.007","article-title":"Epstein\u2013Barr virus-mediated immune evasion in tumor promotion","volume":"46","author":"Yuan","year":"2025","journal-title":"Trends Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509927","article-title":"EBV-specific T-cell immunity: relevance for multiple sclerosis","volume":"15","author":"Behrens","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu5110","article-title":"Epstein-Barr virus infection promotes T cell dysregulation in a humanized mouse model of multiple sclerosis","volume":"11","author":"Allanach","year":"2025","journal-title":"Sci Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molimm.2024.05.003","article-title":"IFN-\u03b1 affects Th17\/Treg cell balance through c-Maf and associated with the progression of EBV- SLE","volume":"171","author":"Zhang","year":"2024","journal-title":"Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3 \u2014 potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03075-w","article-title":"Mechanism of EBV inducing anti-tumour immunity and its therapeutic use","volume":"590","author":"Choi","year":"2021","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01622-1","article-title":"Dynamic single-cell mapping unveils Epstein\u2013Barr virus-imprinted T-cell exhaustion and on-treatment response","volume":"8","author":"Qiu","year":"2023","journal-title":"Signal Transd. Targ. Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-4321","article-title":"Epstein\u2013Barr virus\u2013encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1","volume":"81","author":"Ge","year":"2021","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","article-title":"EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001588","article-title":"EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells","volume":"8","author":"Huo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41467-023-37614-6","article-title":"Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction","volume":"14","author":"Gong","year":"2023","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis \u2014 from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01699-6","article-title":"Multiple sclerosis patient derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease","volume":"9","author":"Soldan","year":"2024","journal-title":"Nat Microbiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2418783122","article-title":"A disease-specific convergence of host and Epstein\u2013Barr virus genetics in multiple sclerosis","volume":"122","author":"Mechelli","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.2793","article-title":"EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity","volume":"177","author":"Wang","year":"2006","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09378-0","article-title":"EBV induces CNS homing of B cells attracting inflammatory T cells","volume":"646","author":"L\u00e4derach","year":"2025","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.935749","article-title":"Integrated analysis of bulk and single-cell RNA sequencing reveals the interaction of PKP1 and tumor-infiltrating B cells and their therapeutic potential for nasopharyngeal carcinoma","volume":"13","author":"Huang","year":"2022","journal-title":"Front Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001004","article-title":"Exosomes from subjects with multiple sclerosis express EBV-derived proteins and activate monocyte-derived macrophages","volume":"8","author":"Mrad","year":"2021","journal-title":"Neurol Neuroimmunol. Neuroinflamm"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425670122","article-title":"Epstein\u2013Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging","volume":"122","author":"Orr","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008375","article-title":"EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303913","article-title":"Single\u2010cell analysis reveals Malignant cells reshape the cellular landscape and foster an immunosuppressive microenvironment of extranodal NK\/T\u2010cell lymphoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2706","article-title":"Epstein\u2013Barr virus-induced VEGF and GM-CSF drive nasopharyngeal carcinoma metastasis via recruitment and activation of macrophages","volume":"77","author":"Huang","year":"2017","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","article-title":"Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis","volume":"186","author":"Vietzen","year":"2023","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030646","article-title":"Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes In Vitro","volume":"198","author":"Bickham","year":"2003","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2009.36","article-title":"EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein","volume":"6","author":"Chen","year":"2009","journal-title":"Cell Mol Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.10.3725","article-title":"Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4","volume":"99","author":"Li","year":"2002","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242552","article-title":"EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape","volume":"43","author":"Severa","year":"2013","journal-title":"Eur J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet Lond. Engl"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res Off. J Am Assoc Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J BioMed Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin Cancer Res Off. J Am Assoc Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.2024.42.23_suppl.139","article-title":"Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial","volume":"42","author":"Peng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1182\/blood-2023-182556","article-title":"Ksd-101 in patients with EBV-associated hematologic neoplasms: results from an ongoing phase I clinical study","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1038\/s41467-024-48031-8","article-title":"Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27270","article-title":"New horizons for multiple sclerosis therapy: 2025 and beyond","volume":"98","author":"Sabatino","year":"2025","journal-title":"Ann Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N. Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030929","article-title":"Advances in targeted therapy for systemic lupus erythematosus: Current treatments and novel approaches","volume":"26","author":"Saegusa","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet Lond. Engl"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13473","article-title":"Modulation of the tumor microenvironment by Epstein\u2010Barr virus latent membrane protein 1 in nasopharyngeal carcinoma","volume":"109","author":"Yoshizaki","year":"2018","journal-title":"Cancer Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","article-title":"Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011934","article-title":"EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation","volume":"20","author":"Xu","year":"2024","journal-title":"PloS Pathog"},{"key":"B73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-00376-4","article-title":"Targeting the signaling in Epstein\u2013Barr virus-associated diseases: mechanism, regulation, and clinical study","volume":"6","author":"Cao","year":"2021","journal-title":"Signal Transd. Targ. Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235780","article-title":"Functional implications of Epstein-Barr virus lytic genes in carcinogenesis","volume":"14","author":"Yap","year":"2022","journal-title":"Cancers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:52:09Z","timestamp":1778219529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2026.1794394"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1794394","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1794394"}}